Skip to main content
SpringerLink
Log in

Neonatal Sepsis

Epidemiology and Management

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Neonatal sepsis is uncommon (2–4 per 1000 live births in developed countries), but the rate increases dramatically in premature newborns and those born to mothers with infections or prolonged rupture of the fetal membranes. While infections caused by organisms contracted from the mother at birth have decreased in the past two decades, there has been an increase in nosocomial infections. Today, most infants with sepsis have been hospitalized in neonatal intensive care units for weeks or months because of extreme prematurity, or because of a congenital malformation or surgical condition. Antimicrobial therapy is usually begun prior to the isolation of a pathogen and is based upon knowledge of the likely microbes in the particular clinical situation.

The number of antimicrobial agents that can be safely used in neonates is relatively small, and dose administration usually needs to be adjusted based upon birthweight and post-gestational age. The decision whether to treat with antimicrobials should be made with consideration of the history, physical examination, and laboratory data. One should also consider the effects of the use of antimicrobials on the flora of the care unit. Bacterial resistance in the resident flora of the unit has become a major problem where there has been indiscriminate use of broad-spectrum agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Table VI
Fig. 2

Similar content being viewed by others

Article 19 June 2019

Muhammed Ershad, Ahmed Mostafa, … David Vearrier

References

  1. Gladstone IM, Ehrenkranz RA, Edberg SC, et al. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990; 9: 819–25

    Article  PubMed  CAS  Google Scholar 

  2. Almuneef MA, Baltimore RS, Farrel PA, et al. Molecular typing demonstrating transmission of gram-negative rods in a neonatal intensive care unit in the absence of a recognized epidemic. Clin Infect Dis 2001; 32: 221–7

    Article  Google Scholar 

  3. Baltimore RS, Huie SM, Meek JI, et al. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001; 108: 1094–8

    Article  PubMed  CAS  Google Scholar 

  4. Baltimore RS. Perinatal bacterial and fungal infections. In: Jenson HB, Baltimore RS, editors. Pediatric infectious diseases: principles and practice. 2nd ed. Philadelphia (PA): WB Saunders Co., 2002: 1119–34

    Google Scholar 

  5. Baltimore RS. Late, late-onset infections in the nursery. Yale J Biol Med 1988; 61: 501–6

    PubMed  CAS  Google Scholar 

  6. Klein JO. Bacterial sepsis and meningitis. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia (PA): WB Saunders Co., 2000: 943–98

    Google Scholar 

  7. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: revised guidelines from the CDC. MMWR Morb Mortal Wkly Rep 2002; 51(RR11): 1–12

    Google Scholar 

  8. Stoll BJ, Gordon T, Korones SB, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 72–80

    Article  PubMed  CAS  Google Scholar 

  9. Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years’ experience with an antibacterial control program. Infect Control Hosp Epidemiol 1999; 20: 242–6

    Article  PubMed  CAS  Google Scholar 

  10. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. New Engl J Med 2000; 342: 15–20

    Article  PubMed  CAS  Google Scholar 

  11. Philip AGS. The changing face of neonatal infection: experience at a regional medical center. Pediatr Infect Dis J 1994; 13: 1098–102

    Article  PubMed  CAS  Google Scholar 

  12. Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13: 1110–6

    PubMed  CAS  Google Scholar 

  13. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report for the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 63–71

    Article  PubMed  CAS  Google Scholar 

  14. Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996; 98: 357–61

    PubMed  CAS  Google Scholar 

  15. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294: 753–6

    Article  PubMed  CAS  Google Scholar 

  16. Edwards MS, Baker CJ. Group B streptococcal infections. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia (PA): WB Saunders Co., 2000: 1091–156

    Google Scholar 

  17. Manroe BL, Weinberg AG, Rosenfeld CR, et al. The neonatal blood count in health and disease (1): reference values for neutrophilic cells. J Pediatr 1979; 95: 89–98

    Article  PubMed  CAS  Google Scholar 

  18. Enguix A, Rey C, Concha A, et al. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001; 27: 211–5

    Article  PubMed  CAS  Google Scholar 

  19. Hatherill M, Tibby SM, Sykes K, et al. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child 1999; 81: 417–21

    Article  PubMed  CAS  Google Scholar 

  20. Gendrel D, Assicot M, Raymond J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996; 128: 570–3

    Article  PubMed  CAS  Google Scholar 

  21. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs viral infections. Pediatr Infect Dis J 1999; 18: 875–81

    Article  PubMed  CAS  Google Scholar 

  22. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000; 19(8): 679–87

    Article  PubMed  CAS  Google Scholar 

  23. Mehr S, Doyle LW. Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J 2000; 19: 879–87

    Article  PubMed  CAS  Google Scholar 

  24. Ng PC, Cheng SH, Chui KM, et al. Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child 1997; 77: F221–7

    Article  CAS  Google Scholar 

  25. Doellner H, Arntzen KJ, Haereid PE, et al. Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998; 132: 295–9

    Article  PubMed  CAS  Google Scholar 

  26. Franz AR, Steinbach G, Kron M, et al. Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics 1999; 104: 447–53

    Article  PubMed  CAS  Google Scholar 

  27. Weirich E, Rabin RL, Maldonado Y, et al. Neutrophil CD11b expression as a diagnostic marker for early-onset neonatal infection. J Pediatr 1998; 132: 445–51

    Article  PubMed  CAS  Google Scholar 

  28. Ehl S, Gering B, Bartmann P, et al. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 1997; 99: 216–21

    Article  PubMed  CAS  Google Scholar 

  29. Philip AGS, Hewitt JR. Early diagnosis of neonatal sepsis. Pediatrics 1980; 65: 1036–41

    PubMed  CAS  Google Scholar 

  30. Philip AGS. Decreased use of antibiotics using a neonatal screening technique. J Pediatr 1981; 98: 795–9

    Article  PubMed  CAS  Google Scholar 

  31. Schwersenski J, McIntyre L, Bauer CR. Lumbar puncture frequency and cerebrospinal fluid analysis in the neonate. Am J Dis Child 1991; 145: 54–8

    PubMed  CAS  Google Scholar 

  32. Fonseca SNS, Ehrenkranz RA, Baltimore RS. Epidemiology of antibiotic use in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1994; 15: 156–62

    Article  PubMed  CAS  Google Scholar 

  33. Young TE, Mangum B. Neofax®: a manual of drugs used in neonatal care. 15th ed. Raleigh (NC): Acorn Publishing, 2002

    Google Scholar 

  34. Nelson JD, Bradley JS. 2000–2001 Nelson’s pocket book of pediatric antimicrobial therapy. 14th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2000

    Google Scholar 

  35. The medical letter on drugs and therapeutics: handbook of antimicrobial therapy. 16th ed. New York: The Medical Letter, 2002

  36. Bryan CS, John Jr JF, Pai S, et al. Gentamicin vs cefotaxime for therapy of neonatal sepsis: relationship to drug resistance. Am J Dis Child 1985; 139: 1086–9

    PubMed  CAS  Google Scholar 

  37. De Man P, Verhoeven BAN, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973–8

    Article  PubMed  Google Scholar 

  38. Reed MD, Blumer JL. Anti-infective therapy. In: Jenson HB, Baltimore RS, editors. Pediatric infectious diseases: principles and practice. 2nd ed. Philadelphia (PA): WB Saunders Co, 2002: 147–215

    Google Scholar 

  39. Vitale R, Baltimore RS. Pediatric aminoglycoside dosing guidelines. New Haven (CT): Yale-New Haven Hospital, 2002

    Google Scholar 

  40. Cairo MS, Worcester CC, Rucker RW, et al. Randomized trial of granulocyte transfusion versus immune globulin therapy for neonatal neutropenia and sepsis. J Pediatr 1992; 120: 281–5

    Article  PubMed  CAS  Google Scholar 

  41. Miura E, Procianoy RS, Bittar C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30–5

    Article  PubMed  CAS  Google Scholar 

  42. Bilgin K, Yaramis A, Haspolat K, et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36–41

    Article  PubMed  CAS  Google Scholar 

  43. Bernstein HM, Calhoun DA, Christensen RD. Use of myeloid colony-stimulating factors in neonates with septicemia. Curr Opin Pediatr 2002; 14: 91–4

    Article  PubMed  Google Scholar 

  44. Berger M. Use of intravenously administered immune globulin in newborn infants: prophylaxis, treatment, both, or neither? J Pediatr 1991; 118: 557–9

    Article  PubMed  CAS  Google Scholar 

  45. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for the prevention and treatment of neonatal sepsis. Pediatrics 1997; 99(2): E2

    Article  PubMed  CAS  Google Scholar 

  46. Giroir BP. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics? Curr Opin Pediatr 2003; 15: 92–6

    Article  PubMed  Google Scholar 

  47. Van den Anker JN, van Popele NML, Sauer PJJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995; 39: 1391–7

    Article  PubMed  Google Scholar 

  48. Sanchez PJ, Siegel JD, Fishein J. Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 1991; 10: 239–43

    Article  PubMed  CAS  Google Scholar 

  49. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9: 51–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut, 06520-8064, USA

    Robert S. Baltimore

Authors
  1. Robert S. Baltimore
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baltimore, R.S. Neonatal Sepsis. Pediatr-Drugs 5, 723–740 (2003). https://doi.org/10.2165/00148581-200305110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200305110-00002

Keywords

Search

Navigation